Adicet Bio, Inc. (ACET) EBITDA
- 2026-06-30: Basis Reported; EBITDA (m); Operating income -$22.30M; Depreciation and amortization (m).
- 2026-03-31: Basis Reported; EBITDA (m); Operating income -$21.57M; Depreciation and amortization (m).
- 2025-09-30: Basis Reported; EBITDA (m); Operating income -$27.95M; Depreciation and amortization (m).
- 2025-06-30: Basis Reported; EBITDA (m); Operating income -$32.39M; Depreciation and amortization (m).
Historical EBITDA
EBITDA 3 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | Reported | (m) | -$22.30M | (m) | (m) | (m) | $202.00K* | -$19.82M* | (m) | $18.45M | (m) | $143.00K |
| 2026-03-31 | Reported | (m) | -$21.57M | (m) | (m) | (m) | $37.00K | -$21.49M | (m) | $17.49M | (m) | $0.00 |
| 2025-09-30 | Reported | (m) | -$27.95M | (m) | (m) | (m) | $209.00K* | -$22.31M* | (m) | $22.85M | (m) | $0.00 |
| 2025-06-30 | Reported | (m) | -$32.39M | (m) | (m) | (m) | $47.00K* | -$26.63M* | (m) | $28.42M | (m) | $0.00 |
| 2025-03-31 | Reported | (m) | -$29.89M | (m) | (m) | (m) | $1.49M | -$25.40M | (m) | $22.81M | (m) | $0.00 |
| 2024-09-30 | Reported | (m) | -$33.15M | (m) | (m) | (m) | $401.00K* | -$22.01M* | (m) | $26.25M | (m) | $0.00 |
| 2024-06-30 | Reported | (m) | -$32.85M | (m) | (m) | (m) | $302.00K* | -$23.42M* | (m) | $25.90M | (m) | $0.00 |
| 2024-03-31 | Reported | (m) | -$30.87M | (m) | (m) | (m) | $239.00K | -$22.85M | (m) | $23.90M | (m) | $0.00 |
| 2023-09-30 | Reported | (m) | -$52.26M | (m) | (m) | (m) | $906.00K* | -$21.24M* | (m) | $26.17M | (m) | $0.00 |
| 2023-06-30 | Reported | (m) | -$34.89M | (m) | (m) | (m) | $1.51M* | -$24.90M* | (m) | $28.36M | (m) | $0.00 |
| 2023-03-31 | Reported | (m) | -$33.32M | (m) | (m) | (m) | $1.92M | -$24.09M | (m) | $26.76M | (m) | $0.00 |
| 2022-09-30 | Reported | (m) | -$22.98M | (m) | (m) | (m) | $4.81M* | -$15.33M* | (m) | $16.57M | (m) | $0.00 |
| 2022-06-30 | Reported | (m) | -$22.71M | (m) | (m) | (m) | $2.85M* | -$14.71M* | (m) | $16.18M | (m) | $0.00 |
| 2022-03-31 | Reported | (m) | $4.71M | (m) | (m) | (m) | $2.63M | $4.11M | (m) | $13.48M | (m) | $0.00 |
| 2021-09-30 | Reported | (m) | -$13.71M | (m) | (m) | (m) | $7.18M* | -$9.68M* | (m) | $11.93M | (m) | $11.00K |
| 2021-06-30 | Reported | (m) | -$10.83M | (m) | (m) | (m) | $2.13M* | -$12.78M* | (m) | $10.62M | (m) | -$77.00K |
| 2021-03-31 | Reported | (m) | -$21.35M | (m) | (m) | (m) | $658.00K | -$15.15M | (m) | $11.74M | (m) | -$48.00K |
| 2020-09-30 | Reported | (m) | -$13.65M | (m) | (m) | (m) | $218.00K* | -$7.85M* | (m) | $8.94M | (m) | $3.00K |
| 2020-06-30 | Reported | (m) | -$8.63M | (m) | (m) | (m) | $117.00K* | -$12.01M* | (m) | $8.68M | (m) | $0.00 |
| 2020-03-31 | Reported | (m) | -$7.56M | (m) | (m) | (m) | $295.00K | -$8.35M | (m) | $7.03M | (m) | -$2.68M |
| 2019-12-31 | Reported | (m) | -$29.44M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-09-30 | Reported | (m) | -$15.22M | (m) | (m) | (m) | $563.00K* | $5.60M* | (m) | $6.33M | (m) | $12.00K |
| 2019-06-30 | Reported | (m) | -$19.17M | (m) | (m) | (m) | $24.00K* | -$14.18M* | (m) | $16.55M | (m) | $10.00K |
| 2019-03-31 | Reported | (m) | -$11.69M | (m) | (m) | (m) | $24.00K | -$12.05M | (m) | $8.85M | (m) | $9.00K |
| 2018-12-31 | Reported | (m) | -$6.36M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-09-30 | Reported | (m) | -$9.03M | (m) | (m) | (m) | $29.00K* | -$10.72M* | (m) | $6.76M | (m) | (m) |
| 2018-06-30 | Reported | (m) | -$14.11M | (m) | (m) | (m) | $26.00K* | -$9.78M* | (m) | $11.85M | (m) | (m) |
| 2018-03-31 | Reported | (m) | -$10.20M | (m) | (m) | (m) | $278.00K | -$7.30M | (m) | $8.11M | (m) | (m) |
| 2017-12-31 | Reported | (m) | -$7.52M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-09-30 | Reported | (m) | -$3.94M | (m) | (m) | (m) | -$12.00K* | -$3.86M* | (m) | $3.33M | (m) | (m) |
| 2017-06-30 | Reported | (m) | -$4.06M | (m) | (m) | (m) | (m) | (m) | (m) | $3.42M | (m) | (m) |
| 2017-03-31 | Reported | (m) | -$3.36M | (m) | (m) | (m) | (m) | (m) | (m) | $3.29M | (m) | (m) |
EBITDA 12 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | Reported | (m) | -$122.11M | (m) | (m) | (m) | $1.74M | -$95.25M | (m) | $99.13M | (m) | $0.00 |
| 2024-12-31 | Reported | (m) | -$127.61M | (m) | (m) | (m) | $1.12M | -$92.38M | (m) | $99.32M | (m) | $0.00 |
| 2023-12-31 | Reported | (m) | -$152.04M | (m) | (m) | (m) | $4.46M | -$93.72M | (m) | $106.04M | (m) | $0.00 |
| 2022-12-31 | Reported | (m) | -$72.55M | (m) | (m) | (m) | $16.78M | -$44.77M | (m) | $71.25M | (m) | $0.00 |
| 2021-12-31 | Reported | (m) | -$61.43M | (m) | (m) | (m) | $13.05M | -$51.05M | (m) | $48.94M | (m) | -$125.00K |
| 2020-12-31 | Reported | (m) | -$39.19M | (m) | (m) | (m) | $990.00K | -$41.55M | (m) | $34.33M | (m) | -$2.81M |
| 2020-09-30 | Rolling | (m) | -$59.28M* | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | Rolling | (m) | -$60.85M* | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-03-31 | Rolling | (m) | -$71.39M* | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | Reported | (m) | -$31.39M | (m) | (m) | (m) | $1.07M | -$27.88M | (m) | $23.69M | (m) | $19.00K |
| 2019-12-31 | Rolling | (m) | -$75.52M* | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-09-30 | Rolling | (m) | -$52.45M* | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-06-30 | Rolling | (m) | -$46.25M* | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-03-31 | Rolling | (m) | -$41.20M* | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-12-31 | Reported | (m) | -$14.96M | (m) | (m) | (m) | $876.00K | -$18.18M | (m) | $14.72M | (m) | -$589.00K |
| 2018-12-31 | Rolling | (m) | -$39.70M* | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-09-30 | Rolling | (m) | -$40.87M* | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-06-30 | Rolling | (m) | -$35.78M* | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-03-31 | Rolling | (m) | -$25.73M* | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-12-31 | Reported | (m) | -$18.88M | (m) | (m) | (m) | $44.00K | -$10.98M | (m) | $16.84M | (m) | $0.00 |
| 2017-12-31 | Rolling | (m) | -$18.88M* | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |